Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer

A. Zambelli, F. S. Robustelli della Cuna, L. Ponchio, G. Ucci, G. A. Da Prada, G. Robustelli della Cuna

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aims. Anthracyclines-taxanes containing regimens are widely used for breast cancer treatment both in neoadjuvant-adjuvant setting and in metastatic disease. Recently high-dose chemotherapy (HDC) with autologous stem cell support has been introduced as adjuvant treatment for high-risk primary breast cancer and for selected subsets of women with metastatic disease. Therefore, salvage treatment for previously treated patients with progressive disease becomes even more problematic. A regimen of continuous infusion of fluorouracil (FU) and vinorelbine (VNR) has been evaluated in heavily pretreated metastatic breast cancer patients. Patients and methods. Forty-eight women, median age 52 years, with previously treated breast cancer entered the study. All but one received more than one line of prior systemic chemotherapy for metastatic disease. Furthermore 14 women had undergone HDC with peripheral blood progenitor cells transplantation in adjuvant setting (6 pts), or metastatic disease (8 pts). Treatment consisted of four-day infusion of FU (1000mg/m2/day) plus VNR (20 mg/m2/iv. day 1 and 5), recycled every 3 weeks for a total of six courses. Drugs administration was discontinued for G4 toxicity, tumor progression or patient's refusal. Results. Twenty PR and four CR for an overall response rate of 50% (95%C.I. 36-64%) were recorded. The therapeutic efficacy of the tested regimen was documented both in patients unresponsive to previous anthracyclines-taxanes combinations and in those relapsing after HDC. The median duration of response was 9 months and median survival 16 months. One third of patients experienced Grade-3 stomatitis-mucositis, hematological toxicity was mild and no cardiac toxicity was observed. Twentyfive women (52%) suffered from infusion-related phlebitis (in half of patients a central venous device was necessary at some point of the treatment program). Conclusions. The combination of FU infusion and VNR iv is an effective salvage treatment for heavily pre-treated metastatic breast cancer patients, and may represent a valid alternative when other cytotoxic regimens are not feasible.

Original languageEnglish
Pages (from-to)241-247
Number of pages7
JournalBreast Cancer Research and Treatment
Volume61
Issue number3
DOIs
Publication statusPublished - 2000

Fingerprint

Salvage Therapy
Fluorouracil
Breast Neoplasms
Drug Therapy
Taxoids
Anthracyclines
Stem Cells
Therapeutics
Phlebitis
Stomatitis
Mucositis
vinorelbine
Cell Transplantation
Blood Cells
Equipment and Supplies
Survival

Keywords

  • Advanced breast cancer
  • Continuous infusion chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zambelli, A., Robustelli della Cuna, F. S., Ponchio, L., Ucci, G., Da Prada, G. A., & Robustelli della Cuna, G. (2000). Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer. Breast Cancer Research and Treatment, 61(3), 241-247. https://doi.org/10.1023/A:1006462023110

Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer. / Zambelli, A.; Robustelli della Cuna, F. S.; Ponchio, L.; Ucci, G.; Da Prada, G. A.; Robustelli della Cuna, G.

In: Breast Cancer Research and Treatment, Vol. 61, No. 3, 2000, p. 241-247.

Research output: Contribution to journalArticle

Zambelli, A, Robustelli della Cuna, FS, Ponchio, L, Ucci, G, Da Prada, GA & Robustelli della Cuna, G 2000, 'Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer', Breast Cancer Research and Treatment, vol. 61, no. 3, pp. 241-247. https://doi.org/10.1023/A:1006462023110
Zambelli, A. ; Robustelli della Cuna, F. S. ; Ponchio, L. ; Ucci, G. ; Da Prada, G. A. ; Robustelli della Cuna, G. / Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer. In: Breast Cancer Research and Treatment. 2000 ; Vol. 61, No. 3. pp. 241-247.
@article{0340b8ac1b314aa2aba52c366ee217b9,
title = "Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer",
abstract = "Aims. Anthracyclines-taxanes containing regimens are widely used for breast cancer treatment both in neoadjuvant-adjuvant setting and in metastatic disease. Recently high-dose chemotherapy (HDC) with autologous stem cell support has been introduced as adjuvant treatment for high-risk primary breast cancer and for selected subsets of women with metastatic disease. Therefore, salvage treatment for previously treated patients with progressive disease becomes even more problematic. A regimen of continuous infusion of fluorouracil (FU) and vinorelbine (VNR) has been evaluated in heavily pretreated metastatic breast cancer patients. Patients and methods. Forty-eight women, median age 52 years, with previously treated breast cancer entered the study. All but one received more than one line of prior systemic chemotherapy for metastatic disease. Furthermore 14 women had undergone HDC with peripheral blood progenitor cells transplantation in adjuvant setting (6 pts), or metastatic disease (8 pts). Treatment consisted of four-day infusion of FU (1000mg/m2/day) plus VNR (20 mg/m2/iv. day 1 and 5), recycled every 3 weeks for a total of six courses. Drugs administration was discontinued for G4 toxicity, tumor progression or patient's refusal. Results. Twenty PR and four CR for an overall response rate of 50{\%} (95{\%}C.I. 36-64{\%}) were recorded. The therapeutic efficacy of the tested regimen was documented both in patients unresponsive to previous anthracyclines-taxanes combinations and in those relapsing after HDC. The median duration of response was 9 months and median survival 16 months. One third of patients experienced Grade-3 stomatitis-mucositis, hematological toxicity was mild and no cardiac toxicity was observed. Twentyfive women (52{\%}) suffered from infusion-related phlebitis (in half of patients a central venous device was necessary at some point of the treatment program). Conclusions. The combination of FU infusion and VNR iv is an effective salvage treatment for heavily pre-treated metastatic breast cancer patients, and may represent a valid alternative when other cytotoxic regimens are not feasible.",
keywords = "Advanced breast cancer, Continuous infusion chemotherapy",
author = "A. Zambelli and {Robustelli della Cuna}, {F. S.} and L. Ponchio and G. Ucci and {Da Prada}, {G. A.} and {Robustelli della Cuna}, G.",
year = "2000",
doi = "10.1023/A:1006462023110",
language = "English",
volume = "61",
pages = "241--247",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer

AU - Zambelli, A.

AU - Robustelli della Cuna, F. S.

AU - Ponchio, L.

AU - Ucci, G.

AU - Da Prada, G. A.

AU - Robustelli della Cuna, G.

PY - 2000

Y1 - 2000

N2 - Aims. Anthracyclines-taxanes containing regimens are widely used for breast cancer treatment both in neoadjuvant-adjuvant setting and in metastatic disease. Recently high-dose chemotherapy (HDC) with autologous stem cell support has been introduced as adjuvant treatment for high-risk primary breast cancer and for selected subsets of women with metastatic disease. Therefore, salvage treatment for previously treated patients with progressive disease becomes even more problematic. A regimen of continuous infusion of fluorouracil (FU) and vinorelbine (VNR) has been evaluated in heavily pretreated metastatic breast cancer patients. Patients and methods. Forty-eight women, median age 52 years, with previously treated breast cancer entered the study. All but one received more than one line of prior systemic chemotherapy for metastatic disease. Furthermore 14 women had undergone HDC with peripheral blood progenitor cells transplantation in adjuvant setting (6 pts), or metastatic disease (8 pts). Treatment consisted of four-day infusion of FU (1000mg/m2/day) plus VNR (20 mg/m2/iv. day 1 and 5), recycled every 3 weeks for a total of six courses. Drugs administration was discontinued for G4 toxicity, tumor progression or patient's refusal. Results. Twenty PR and four CR for an overall response rate of 50% (95%C.I. 36-64%) were recorded. The therapeutic efficacy of the tested regimen was documented both in patients unresponsive to previous anthracyclines-taxanes combinations and in those relapsing after HDC. The median duration of response was 9 months and median survival 16 months. One third of patients experienced Grade-3 stomatitis-mucositis, hematological toxicity was mild and no cardiac toxicity was observed. Twentyfive women (52%) suffered from infusion-related phlebitis (in half of patients a central venous device was necessary at some point of the treatment program). Conclusions. The combination of FU infusion and VNR iv is an effective salvage treatment for heavily pre-treated metastatic breast cancer patients, and may represent a valid alternative when other cytotoxic regimens are not feasible.

AB - Aims. Anthracyclines-taxanes containing regimens are widely used for breast cancer treatment both in neoadjuvant-adjuvant setting and in metastatic disease. Recently high-dose chemotherapy (HDC) with autologous stem cell support has been introduced as adjuvant treatment for high-risk primary breast cancer and for selected subsets of women with metastatic disease. Therefore, salvage treatment for previously treated patients with progressive disease becomes even more problematic. A regimen of continuous infusion of fluorouracil (FU) and vinorelbine (VNR) has been evaluated in heavily pretreated metastatic breast cancer patients. Patients and methods. Forty-eight women, median age 52 years, with previously treated breast cancer entered the study. All but one received more than one line of prior systemic chemotherapy for metastatic disease. Furthermore 14 women had undergone HDC with peripheral blood progenitor cells transplantation in adjuvant setting (6 pts), or metastatic disease (8 pts). Treatment consisted of four-day infusion of FU (1000mg/m2/day) plus VNR (20 mg/m2/iv. day 1 and 5), recycled every 3 weeks for a total of six courses. Drugs administration was discontinued for G4 toxicity, tumor progression or patient's refusal. Results. Twenty PR and four CR for an overall response rate of 50% (95%C.I. 36-64%) were recorded. The therapeutic efficacy of the tested regimen was documented both in patients unresponsive to previous anthracyclines-taxanes combinations and in those relapsing after HDC. The median duration of response was 9 months and median survival 16 months. One third of patients experienced Grade-3 stomatitis-mucositis, hematological toxicity was mild and no cardiac toxicity was observed. Twentyfive women (52%) suffered from infusion-related phlebitis (in half of patients a central venous device was necessary at some point of the treatment program). Conclusions. The combination of FU infusion and VNR iv is an effective salvage treatment for heavily pre-treated metastatic breast cancer patients, and may represent a valid alternative when other cytotoxic regimens are not feasible.

KW - Advanced breast cancer

KW - Continuous infusion chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0033861342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033861342&partnerID=8YFLogxK

U2 - 10.1023/A:1006462023110

DO - 10.1023/A:1006462023110

M3 - Article

VL - 61

SP - 241

EP - 247

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -